Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms

Anti-angiogenic therapy used in treatment of metastatic colorectal cancer (mCRC) inevitably succumbs to treatment resistance. Upregulation of MET may play an essential role to acquired anti-VEGF resistance. We previously reported that cabozantinib (XL184), an inhibitor of receptor tyrosine kinases (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Scott, Aaron J, Bagby, Stacey M, Yahn, Rachel, Huber, Kendra M, Serkova, Natalie J, Nguyen, Anna, Kim, Jihye, Thorburn, Andrew, Vogel, Jon, Quackenbush, Kevin S., Capasso, Anna, Schreiber, Anna, Blatchford, Patrick, Klauck, Peter J, Pitts, Todd M., Eckhardt, S. Gail, Messersmith, Wells
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168336/
https://ncbi.nlm.nih.gov/pubmed/30026382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0131
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares